Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

This study is ongoing, but not recruiting participants.

Study NCT00030667 Information provided by National Cancer Institute (NCI)

First Received: February 14, 2002 Last Updated: October 15, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 2007 Jan 29; [Epub ahead of print]

Bond M, Bernstein ML, Pappo A, et al.: Phase 2 trial of imatinib mesylate (IM) for treatment of recurrent or refractory pediatric solid tumors: a Children's Oncology Group Study. [Abstract] J Clin Oncol 23 (Suppl 16): A-8520, 805s, 2005.